抗原|新冠防治进入新阶段！4000字长文解读《新型冠状病毒肺炎诊疗方案（试行第九版）》丨奇点深度( 四 ) 长文|防治|诊疗|核酸|密克|罗米

[15].Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. The Lancet, 2022.
[16].Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2[J]. Nature, 2022, 602(7898): 676-681..
[17].Piccoli L, Park Y J, Tortorici M A, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology[J]. Cell, 2020, 183(4): 1024-1042. e21.
[18].Corti D, Purcell L A, Snell G, et al. Tackling COVID-19 with neutralizing monoclonal antibodies[J]. Cell, 2021.
[19].Zhang Y, Hao X, Ma J, et al. Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies[J]. medRxiv, 2021.
[20]. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages[J]. Nature, 2022: 1-1.
[21].Yan W, Zheng Y, Zeng X, et al. Structural biology of SARS-CoV-2: open the door for novel therapies[J]. Signal Transduction and Targeted Therapy, 2022, 7(1): 1-28.
[22].Zhang Y, Hao X, Ma J, et al. Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies[J]. medRxiv, 2021.
[24].Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5(2):297-305. doi:10.4161/mabs.23684
[25].https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-paxlovid-drug-drug-interactions/
【抗原|新冠防治进入新阶段！4000字长文解读《新型冠状病毒肺炎诊疗方案（试行第九版）》丨奇点深度】本文作者丨BioTalker